Induction therapy consisting of alternating cycles of ranimustine, vincristine, melphalan, dexamethasone and interferon α (ROAD-IN) and a randomized comparison of interferon α maintenance in multiple myeloma: A co-operative study in Japan

British Journal of Haematology

Volumn 109, Issue 4, 2000, Pages 805-814

  Wada, Makio ^a   Mizoguchi, Hideaki ^a   Kuriya, Shin Ichiro ^b   Taguchi, Hirokuni ^c   Kawamura, Tsugumichi ^d   Maekawa, Isao ^e   Shimazaki, Chihiro ^f   Sato, Yutaka ^g   Niho, Yoshiyuki ^h   Miyazaki, Tamotsu ⁱ   Shibata, Akira ^j   Kitani, Teruo ^k   Hamajima, Nobuyuki ^l   Ohno, Ryuzo ^m  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b IWATE MEDICAL UNIVERSITY   (Japan)

^c KOCHI MEDICAL SCHOOL   (Japan)

^d HAKODATE CENTRAL GENERAL HOSPITAL   (Japan)

^e ASAHIKAWA CITY HOSPITAL   (Japan)

^f KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^g YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h KYUSHU UNIVERSITY   (Japan)

ⁱ Sapporo Hosp Posts/Telecom of JPN   (Japan)

^j Tachikawa General Hospital   (Japan)

^k SAKAI MUNICIPAL HOSPITAL   (Japan)

^l AICHI CANCER CENTER HOSPITAL   (Japan)

^m HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Interferon maintenance; Multiple myeloma; Prospective randomized trial; Ranimustine; ROAD IN regimen

Indexed keywords

ALPHA INTERFERON; DEXAMETHASONE; MELPHALAN; RANIMUSTINE; RECOMBINANT ALPHA2A INTERFERON; VINCRISTINE; VINCRISTINE SULFATE;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FATIGUE; FEMALE; FEVER; HUMAN; LEUKOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHI-SQUARE DISTRIBUTION; DEXAMETHASONE; HUMANS; INTERFERON-ALPHA; LOGISTIC MODELS; MELPHALAN; MULTIPLE MYELOMA; MUSCLE PROTEINS; MYELOMA PROTEINS; NITROSOUREA COMPOUNDS; PILOT PROJECTS; PROSPECTIVE STUDIES; REMISSION INDUCTION; VINCRISTINE;

EID: 0033866165     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02120.x     Document Type: Article

References (29)

1. Alexanian, R. & Dimopoulos, M. (1994) The treatment of multiple myeloma. New England Journal of Medicine, 330, 484-489.
2. Alexanian, R., Dimopoulos, M., Delasalle, K. & Barlogie, B. (1992) Primary dexamethasone treatment of multiple myeloma. Blood, 80, 887-890.
3. Anderson, H., Scarffe, J.H., Ranson, M., Young, R., Wieringa, G.S., Morgenstern, G.R., Fitzsimmons, L. & Ryder, D. (1995) VAD chemotherapy as remission induction for multiple myeloma. British Journal of Cancer, 71, 326-330.
4. Barlogie, B., Smith, L. & Alexanian, R. (1984) Effective treatments of advanced multiple myeloma refractory to alkylating agents. New England Journal of Medicine, 310, 1353-1356.
5. Blade, J., San Miguel, J.F., Escudero, M.L., Fontanillas, M., Besalduch, J., Gardella, S., Arias, J., Garcia-Conde, J., Carnero, M., Marti, J.M., Rozman, C., Estape, J. & Montserrat, E. (1998) Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology). Leukemia, 12, 1144-1148.
6. Cooper, M.R. (1991) A review of the clinical studies of alpha-interferon in the management of multiple myeloma. Seminars in Oncology, 18 (Suppl. 7), 18-30.
7. Cooper, M.R., Dear, K., McIntyre, O.R., Ozer, H., Ellerton, J., Canellos, G., Bernard, B., Duggan, D., Faragher, D. & Schiffer, C. (1993) A randomized clinical trial comparing melphalan/ prednisone with or without Interferon alpha-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 11, 155-160.
8. Drayson, M.T., Chapman, C.E., Dunn, J.A., Olujohungbe, A.B. & Maclennan, I.C.M. for the MRC Working Party on Leukaemia in Adults. (1998) MRC trial of α2b-interferon maintenance therapy in first plateau phase of multiple myeloma. British Journal of Haematology, 101, 195-202.
9. Gregory, W.M., Richards, M.A. & Malpas, J.S. (1992) Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma. An overview of published trials. Journal of Clinical Oncology, 10, 334-342.
10. Johnson, P.W.M. & Selby, P.J. (1994) The treatment of multiple myeloma - an important MRC trial. British Journal of Cancer, 70, 781-785.
11. Kimura, K., Ogawa, M., Wakui, A., Saito, T., Majima, H., Oguro, M., Sakai, Y., Furue, H., Yamada, K., Ohta, K., Hoshino, A. & Masaoka, T. (1981) Phase I study of 1-(2-chloroethyl)-3-(methylα-D-glucopyranos-6-yl-1-nitrosourea (MCNU). Japanese Journal of Cancer and Chemotherapy, 8, 167-171.
12. Kyle, R.A. (1993) Newer approaches to the management of multiple myeloma. Cancer Supplement, 72, 3489-3494.
13. Ludwig, H., Cohen, A.M., Polliack, A., Huber, H., Nachbaur, D., Senn, H.-J., Morant, R., Eckhardt, S., Gunczler, P., Seewann, H.L., Schuller, J., Rhyner, K., Cavalli, F. & Fritz, E. (1995) Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Annals of Oncology, 6, 467-476.
14. Masaoka, T., Shibata, H., Nagai, K., Kanamaru, A., Kitani, T., Taniguchi, N., Yonezawa, T., Kawagoe, H., Hirata, M., Horiuchi, A., Tsubaki, K., Ohkubo, H., Yasunaga, K., Okamoto, Y., Fujitake, H., Sasada, M. & Nakamura, T. (1985) Clinical phase II study of MCNU (ranomustine) in hematological malignancies. Chemotherapy, 33, 271-278.
15. Oguro, M., Takagi, T. & Takenaga, K. (1985) Dynamic analysis of changing features of tumor cells incubated with antitumor agents in vitro and its application for predictive activity assay of antitumor agents. Japanese Journal of Cancer Research (Gann), 76, 131-141.
16. Oken, M.M. (1994) Standard treatment of multiple myeloma. Mayo Clinic Proceedings, 69, 781-786.
17. Oken, M.M., Kyle, R.A., Greipp, P.R., Kay, N.E., Tsiatis, A., Gregory, S.A., Spiegel, R.J. & O'Connell, M.J. (1996) Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha2b) in patients with multiple myeloma. Leukemia and Lymphoma, 20, 447-452.
18. Oken, M.M., Leong, T., Lenhard, Jr, R.E., Greipp, P.R., Kay, N.E., Van Ness, B., Keimowitz, R.M. & Kyle, R.A. (1999) The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma. Phase III Eastern Cooperative Oncology Group Clinical Trial EST9486. Cancer, 86, 957-968.
19. Osterborg, A., Bjorkholm, M., Bjoreman, M., Brenning, G., Carlson, K., Celsing, F., Gahrton, G., Grimfors, G., Gyllenhammar, H., Hast, R., Johansson, B., Juliusson, G., Jarnmark, M., Kimby, E., Lerner, R., Linder, O., Merk, K., Nilsson, B., Ohrling, M., Paul, C., Simonsson, B., Smedmyr, B., Svedmyr, E., Stalfelt, A.-M., Strander, H., Uden, A.-M., Osby, E. & Mellstedt, H. (1993) Natural interferon-α in combination with melphalan-prednisone versus melphalan-prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. Blood, 81, 1428-1434.
20. Peest, D., Deicher, H., Coldewey, R., Leo, R., Bartl, R., Bartels, H., Braun, H.J., Fett, W., Fischer, J.T., Gobel, B., Harms, P., Henke, R., Hoffmann, L., Kreuser, E.D., Maier, W.D., Meier, C.R., Oertel, J., Petit, M., Planker, M., Platzeck, C., Respondek, M., Schafer, E., Schumacher, K., Stennes, M., Stenzinger, W., Tirier, C., Wagner, H., Weh, H.J., von Wussow, P. & Wysk, J. (1995) A comparison of polychemotherapy and melphalan/predonisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. European Journal of Cancer, 31A, 146-151.
21. Pulsoni, A., Avvisati, G., Petrucci, M.T., Mandelli, F., Giannarelli, D., Lauta, V.M., Tribalto, M. & Pileri, A. (1998) The Italian experience on interferon as maintenance treatment in multiple myeloma: ten years after. Blood, 92, 2184-2186.
22. Salmon, S.E., Crowley, J.J., Grogan, T.M., Finley, P., Pugh, R.P. & Barlogie, B. (1994) Combination chemotherapy, glucocorticoids, and interferon alpha in the treatment of multiple myeloma: a South West Oncology Group Study. Journal of Clinical Oncology, 12, 2405-2414.
23. Samson, D., Gaminara, E., Newland, A., Van de Pette, J., Kearney, J., McCarthy, D., Joyner, M., Aston, L., Mitchell, T., Hamon, M., Barrett, A.J. & Evans, M. (1989) Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet, ii, 882-885.
24. Sekido, S., Ninomiya, K. & Iwasaki, M. (1979) Biologic activity of MCNU: a new antitumor agent. Cancer Treatment Reports, 63, 961-970.
25. Takaue, Y., Watanabe, T., Hoshi, Y., Abe, T., Matsunaga, K., Saito, S., Hirao, A., Kawano, Y., Ninomiya, T., Kuroda, Y., Koyama, T., Suzue, T., Shimokawa, T., Uchiyama, H., Watanabe, A., Matsushita, T., Kikuta, A., Yokobayashi, A., Murakami, R., Manabe, A., Hosoya, R., Ohira, M. & Fujimoto, T. (1991) Effectiveness of high-dose MCNU therapy and hematopoietic stem cell autografts treatment of childhood acute leukemia/ lymphoma with high-risk features. Cancer, 67, 1830-1837.
26. The Myeloma Trialists' Collaborative Group. (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Journal of Clinical Oncology, 16, 3832-3842.
27. Uzuka, Y., Saito, Y. & Ito, T. (1990) Combination chemotherapy of multiple myeloma. Japanese Journal of Cancer and Chemotherapy, 17, 1481-1487.
28. Westin, J., Rodjer, S., Turesson, I., Cortelezzi, A., Hjorth, M. & Zador, G. (1995) Interferon alpha-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. British Journal of Haematology, 89, 561-568.
29. Zee, B., Cole, B., Li, T., Browman, G., James, K., Johnston, D., Sugano, D. & Pater, J. (1998) Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. Journal of Clinical Oncology, 16, 2834-2839.